Dr. Syed M. Kazmi
Claim this profileUT Southwestern/Simmons Cancer Center-Dallas
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
33 drugs studied
Area of expertise
1Colorectal Cancer
Global LeaderStage IV
Stage III
BRAF positive
2Colon Cancer
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Syed M. Kazmi is currently running
ATRA + Bevacizumab + Atezolizumab
for Colorectal Cancer
The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW. 3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.
Recruiting1 award Phase 210 criteria
Chemotherapy + Bevacizumab + Atezolizumab
for Colorectal Cancer
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Recruiting2 awards Phase 31 criteria
More about Syed M. Kazmi
Clinical Trial Related7 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Syed M. Kazmi has experience with
- Atezolizumab
- Nivolumab
- Cetuximab
- Bevacizumab
- Oxaliplatin
- Fluorouracil
Breakdown of trials Syed M. Kazmi has run
Colorectal Cancer
Colon Cancer
Stomach Cancer
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Syed M. Kazmi specialize in?
Syed M. Kazmi focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Syed M. Kazmi currently recruiting for clinical trials?
Yes, Syed M. Kazmi is currently recruiting for 5 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Syed M. Kazmi has studied deeply?
Yes, Syed M. Kazmi has studied treatments such as Atezolizumab, Nivolumab, Cetuximab.
What is the best way to schedule an appointment with Syed M. Kazmi?
Apply for one of the trials that Syed M. Kazmi is conducting.
What is the office address of Syed M. Kazmi?
The office of Syed M. Kazmi is located at: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas 75390 United States. This is the address for their practice at the UT Southwestern/Simmons Cancer Center-Dallas.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.